Skip to main content
Premium Trial:

Request an Annual Quote

Rheumatology Genomic Test Developer Exagen Diagnostics Raises $5.3M

NEW YORK (GenomeWeb News) – Exagen Diagnostics, which develops genomic tests aimed at rheumatology, announced on Monday the completion of a financing round that raised $5.3 million.

The funding will be used to expand the market for the Albuquerque, NM-based firm's brands and further development of near-term pipeline products, it said. Exagen plans to expand its three marketed rheumatology brands — Avise SLE, Avise PG, and Avise MCV — and other products that will help physicians diagnose and treat rheumatologic disorders, company President and CEO Ron Rocca said.

"Many connective tissue diseases are considered chameleon-like or have a wide range of sometimes overlapping symptoms, which adds to the difficulty of correctly diagnosing these diseases," he said in a statement. "It's our goal to arm physicians with the best tools available to help these patients."

Exagen also operates a CLIA-certified laboratory in Vista, Calif.

Tullis Health Investors led the financing round. Other investors include Sun Mountain Capital, Cottonwood Technology Fund, Mesa Verde Venture Partners, and Epic Ventures.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.